Objective: The purpose was to study the effects of flaxseed supplementation as a part of daily diet on serum lipids, fatty acids and plasma enterolactone. Design: Eighty volunteers participated in this clinical nutrition study which was carried out in a controlled, double-blind and cross-over manner. The subjects were randomized to diet sequences AB or BA. Diet A meals contained 1.3 g=100 g ground flaxseed and 5 g=100 g flaxseed oil. Also 3 -4 g=100 of inulin and wheat fiber was added. AB diet with non-supplemented foods served as control. Test subjects were on both diets for 4 weeks separated by a 4-week wash-out period. Fifteen test subjects continued an open part of the study for 4 additional months. Interventions: The dietary intake, basic blood values, serum lipids, fatty acids and enterolactone were measured at baseline, after both intervention periods and during the open study, at baseline and after 2 and 4 months. Serum thiocyanate and blood cadmium were controlled after both intervention periods. Results: The percentage of flaxseed supplemented test food out of total dietary intake was 20% of energy. The test food contained significantly higher amounts of fiber, polyunsaturated fatty acids (PUFAs) and especially a-linolenic acid than the control food.
Introduction
Flaxseed contains putative health promoting factors like nutritional fiber, the phytoestrogen lignan precursors secoisolariciresinol and matairecinol and flaxseed oil with its high concentration of a-linolenic acid. Enterolactone is formed from lignan precursors by intestinal microbial flora.
Recent studies have shown that mammalian lignans may act as chemopreventive agents against hormone-dependent cancers such as breast cancer and prostate cancer (Adlercreutz and Mazur, 1997; Ingram et al, 1997; Tham et al, 1998; Thompson et al, 1996; Tou and Thompson, 1999) and against gastrointestinal tract cancer (Pool-Zobel et al, 2000) . There is also evidence that lignans can lower the risk of myocardial infarction (Vanharanta et al, 1999) . High plasma enterolactone ( > 30 nmol=l) has been found to be associated with low risk of acute coronary events in men (Vanharanta et al, 1999) and with low breast cancer risk in women (Pietinen et al, 2001) . Alpha-linolenic acid shows similar cancer-preventive effects (Tou & Thompson, 1999; Klein et al, 2000; Cognault et al, 2000; De Stefani et al, 2000; Johnston, 1995; Baro et al, 1998) , an inverse association with risk of coronary heart disease (Ascherio et al, 1996) and beneficial effects on hemostatic factors (Allman-Farinelli et al, 1999; Freese & Mutanen, 1997) . Alpha-linolenic acid is involved also in inflammatory diseases by decreasing leukotriene B4 concentration (Shoda et al, 1995; Inui et al, 1996; Geerling et al, 1999) and in atopic disease (Kankaanpää et al, 1999) . Finally, a-linolenic acid seems to have a beneficial role also on brain function (Youdim et al, 2000) .
The purpose of our study was to find out if reasonable amounts of flaxseed and flaxseed oil in processed foods are able to increase the levels of serum a-linolenic acid and enterolactone in healthy subjects to levels optimal for health based on present knowledge.
Subjects
A group of 83 subjects, all employees of a food company, were enrolled in the study. Their personal and family medical history was recorded in the files of the company health center. During screening the basic health of the subjects was evaluated by referring to these records and by clinical examination. The subjects without any chronic illnesses or permanent medication were included. During the screening three of the subjects were excluded because of health reasons: one because of unbalanced type 2 diabetes, one because of familial hypercholesterolemia and the third because of coeliac disease. Lipid profiles were equal in both groups. The subjects were advised not to use any fiber or oil supplements during the study.
Eighty subjects completed the study. There were 62 women participating with a mean age of 42.6 y (s.d. 11.2) and 18 men with a mean age of 45.6 y (s.d. 10.4). There were 22 smokers, 19 women and three men, with a daily cigarette consumption of 10 -30. A written informed consent was obtained after the subjects had been given comprehensive information both written and verbal. The Ethics Committee of The Hospital Mehiläinen approved the study protocol.
The demographic data is presented in Table 1 .
Study design
This randomized, double-blind, cross-over study was conducted in two parts. The subjects were randomized to receive either flaxseed-supplemented food (diet A) or control food (diet B). After 4 weeks' diet and an additional 4-week washout period the diets were reversed. Both test food and control food was developed and prepared by HK-Ruokatalo Oyj, Vantaa, Finland (a major Finnish food company). Ground flaxseed (1.3 g=100 g) and flaxseed oil (5 g=100 g) were added to test food. Also 3 -4 g=100 g of inulin and wheat fiber was added to increase the amount of soluble and insoluble fiber. Analysis of fiber was done by the Technical Research Center of Finland (Espoo, Finland) using Asp's enzymatic gravimetry and fructanes by enzymatic spectrophotometry. All food analyses were done by The Finnish Meat Research Institute (Hämeenlinna, Finland) .
After the double-blind study the subjects were given an option to continue in an open study for 4 months with the flaxseed supplemented food only. The selection and composition of both test food and the control food are presented in Table 2 . All subjects kept daily food records for 3 days before starting the study and during both double-blind periods. The subjects also kept a daily diary of the consumed test or control food. The food portions were served for lunch at the workplace and corresponding food boxes were provided for the weekends. During the open study the subjects consumed daily one portion of flaxseed supplemented food. The subjects were asked about their smoking habits and they were weighed at the beginning and end of both test periods.
Fasting blood samples were taken at the beginning and end of both intervention periods. Samples were collected to determine blood hemoglobin, leukocytes, serum aspartate and alanine amino transferases, alkaline phosphatase, creatinine, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, serum total fatty acids and serum enterolactone. Flaxseed contains cyanogenic glycosides and cadmium. For safety reasons serum thiocyanate and blood cadmium were determined.
During the open study the same blood tests were taken after 2 months and 4 months. The study design is presented in Figure 1 .
Measurements of basic laboratory parameters
All laboratory assays were done in the Clinical Laboratory of The Hospital Mehiläinen, Helsinki, if not otherwise indicated. Measurement of serum lipids was done using Kodak's Vitros 750 autoanalyzer (Rochester, USA). Measurements of serum thiocyanate were performed by the Laboratory of Finnish Institute of Occupational Health, Helsinki. In the method used, thiocyanate in serum was adsorbed on a weak anion exchange resin and eluted with perchlorate. Thiocyanate was quantified by the König reaction using isonicotinic acid and 1,3-dimethyl-barbituric acid. The determination was made with a spectrophotometer at 607 nm. Natural and spiked controls were used for quality control. The day- Effect of flaxseed supplementation S Tarpila et al to-day variation was 5% at a level of 40 mmol=l. According to the accredited laboratory performing the determinations thiocyanate is considered stable in serum and urine for at least half a year at 7 20 C. Serum cadmium was determined by the standardized method by the Laboratory of Finnish Occupational Health, Helsinki.
Measurement of serum fatty acids was done by extracting serum lipids by a modification of Folch et al (1957) using 9 ml of dichloromethane-methanol (2 þ 1 v=v) and the liberated fatty acids were transesterified to methyl esters by acidic methanol (5% H 2 SO 4 ; Stoffel et al, 1959) . The percentage composition of the fatty acid methyl esters was determined by a Hewlett-Packard 6890 (Palo Alto, USA) gas chromatograph with a 25 -m NB 351 fused silica capillary column, diametre 0.32 mm, phase layer 0.20 mm (HNU-Nordion Instruments, Espoo, Finland), and split injection with hydrogen as carrier gas and a temperature program from 180 to 230 C. The fatty acid methyl esters from C14:0 to C22:6 were quantified with a Hewlett Packard Chemstation version A06.01.
Measurement of serum enterolactone was done by TR-FIA (time-resolved fluoroimmunoassay) using a slight modification of the original method (Adlercreutz et al, 1998) in the Folkhälsan Institute for Preventive Medicine, Nutrition and Cancer. The samples were hydrolyzed and extracted before TR-FIA. All assays were carried out together with control samples having three different concentrations. Validation of the method has been published .
Dietary analysis
The habitual diet of the subjects was evaluated with a 3 day food record which included one weekend day. A 63-page booklet in the estimation of portions sizes was used (Pietinen et al, 1988) . Food records were checked and food and nutrient intakes were calculated by the Flamingo computer program using the Finnish nutrient database Fineli (National Public Health Institute, Finland). Fineli includes 210 
Statistical analysis
Statistical analysis was performed following the methods and principles presented by Jones and Kenward for the 2Â2 crossover trial with baseline measurements (Jones & Kenward, 1989) . Direct treatment and carry-over effects were assessed applying parametric (t-tests) and nonparametric methods (Wilcoxon rank-sum tests). The two-sample t-test, in its traditional between-subject form does not account for the within-subject comparison of the cross-over design applied. However, if the two-sample t-test is based on individual contrasts instead of individual measurements, as Jones and Kenward (1989) have presented, the standard two-sample ttest comparing two independent groups offers a simple way to analyze the direct treatment and carry-over effects. All tests were two-sided. The two approaches produced very similar test results. The conventional level of 5% was considered the level of statistical significance when testing the direct treatment effect; with the carry-over effects a less extreme 10% level was applied. Grizzle (1965) suggested that carry-over effects should be tested, as a preliminary test prior to testing for a treatment difference, at the 10% two-sided level rather than at the more conventional 5% level. Before any analysis it was decided to analyze the data according to Grizzle's advise. The conventional 5% level of significance was used when the difference between direct treatment effects was tested. This approach was applied consistently over the data, including the main outcome measures. No evidence for the presence of carry-over effects was found. Analysis of the data on the open study phase was based on changes between the visits (baseline, 2 months and 4 months), one-sample t-tests and Wilcoxon signed ranks tests. No adjustments for multiple comparisons were made. Statistical calculations were carried out using the SAS software. Statistical analysis of the nutrient data was carried out using SAS programs (SAS Institute Inc., 1990) . Changes in nutrients from baseline period to period 1 were tested with analyses of variance between diets A and B. Differences between diets A and B during period 1 and period 2 were analyzed separately with an independent t-test.
All the hypotheses of interest can be tested also using Ftests obtained from an analysis-of-variance table. The twosample t-test approach was used due to its simplicity; there is no need to make any assumptions about the covariance structure, except the same variance in the two groups. With this approach it is also easy to produce the corresponding non-parametric test results.
Results
Energy and energy-adjusted intakes of protein, fats, carbohydrates and alcohol are given in Table 3 . Absolute intakes (g=day) of protein, fats, carbohydrates and fiber (total, waterinsoluble and water-soluble fiber separately) are given in Table 4 . Daily average energy intake was 8356 kJ before intervention, 7856 kJ in diet A (flax group) and 7929 kJ in diet B (control group).
Intake of polyunsaturated fatty acids (PUFA) and fiber was increased in the flax group and remained quite steady in control group from baseline period to period 1. Intake of water-insoluble fiber decreased during both diets, but the decrease was higher in the control diet. Intake of watersoluble fiber increased in both groups, but the increase was significantly higher in the flax group.
Energy-adjusted intake of PUFA and absolute intakes of fiber and water-soluble fiber were greater during the flax diet compared with the control diet in both periods. Absolute intake of PUFA and energy-adjusted intake of carbohydrates were significantly greater during flax diet only during period 2. The composition and the average daily intake of the flax diet (A) is presented in Figures 2 and 3 . 
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There were no changes in the body weight of the test subjects during the intervention periods. There were no significant changes in the basic laboratory values or in the blood lipid values during the double-blind period (Table 5) or during the open period of the study (Table 6 ). There were no differences between men and women with respect to their reaction on the different diets. The group of smokers was too small to be able to calculate the difference of reaction between smokers and non-smokers.
The flaxseed supplemented test food significantly increased the proportions of a-linolenic acid, eicosapentaenoic acid and docosapentaenoic acid in serum lipids whereas the effect on docosahexaenoic acid was statistically nonsignificant (Table 7 and Figures 4 and 5) . The serum enterolactone concentrations were also significantly increased during the double-blind periods and during the open study period (Figures 6 and 7) .
The baseline values of serum thiocyanate and blood cadmium were not determined. After the double-blind periods the concentrations were below the reference values (Table 8) .
Discussion

Fiber
The ground, partly defatted flaxseed contains 40% of fiber of which two-thirds is insoluble and one-thirds soluble. It has been suggested by epidemiological studies that the daily fiber intake of more than 25 g results in lower prevalence of colon polyps and colon cancer (Howe et al, 1992; Trock et al, 1990) .
The commercial processed meats and convenience food lacks fiber very commonly. The flaxseed-supplemented test food increased the fiber intake to 25 -30 g=day ie, into the range that is recommended in the Nordic countries (Nordic Nutrition Recommendations, 1996) . Table 5 Basic laboratory values and blood lipids during the double-blind periods; mean AE s.e.m.
Parameter
Before intervention Diet A, periods 1 and 2 Diet B, periods 1 and 2 Significance Hb (g=l) 140 AE 2 1 3 9 AE 2 1 3 9 AE 2 N S Leukocytes (10Â10 9 =1) 6.0 AE 0.3 5.6 AE 0.3 5.7 AE 0.2 NS ALAT (U=1) 27 AE 2 3 1 AE 2 3 1 AE 3 N S ASAT (U=1) 26 AE 2 2 9 AE 2 2 6 AE 1 N S AFOS (U=1) 115 AE 4 1 1 4 AE 4 1 1 7 AE 5 N S KREA (mmol=l) 80 AE 3 7 6 AE 4 7 7 AE 3 N S S-cholesterol (mmol=l) Figure 4 Serum a-linoenlic acid (percentage of total fatty acids) before and after 4 weeks' randomized flax-diet and control diet. S-a-linolenic acid increased significantly (P < 0.001) during flax-diet in 80 subjects. Figure 6 Serum enterolactone (nmol=l) in 80 subjects before and after randomized flax-diet and control diet periods. S-enterolactone increased significantly during flax-diet (P < 0.001). 
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Enterolactone
Flaxseed is the richest source of the known mammalian lignan precursors secoisolariciresinol and matairesinol (Thompson et al, 1991) . Mammalian lignans enterolactone and enterodiol are formed by intestinal bacteria from these precursors. Processed meat and convenience foods contain only traces of lignans. Supplementation of the test food with flaxseed resulted in the intake of 8 mg=day of lignans, which nearly doubled the serum enterolactone concentration in the test subjects during the flaxseed period and more than doubled it during the open period. These concentrations are considered to reflect low risk with regard to hormone-dependent cancers and they also seem to lower the risk of myocardial infarction. It has been found that a mean serum concentration of 54 nmol=l of enterolactone was associated with a 60% lower risk of myocardial infarction in a controlled prospective population-based case study with 167 coronary heart disease cases and 167 controls in Finland (Vanharanta et al, 1999) .
The Asian diet is very rich in isoflavonoids but low in lignans. The incidence of colon cancer and breast cancer increased in the Japanese population during the 1980s and 1990s in parallel with decreasing consumption of soy foods.
Because soy consumption is very low in Western populations, the main phytoestrogens are the lignans. These compounds are much less estrogenic than the isoflavonoids. The urinary excretion of lignans is associated with fiber intake, particularly with grain fiber intake (Adlercreutz et al, 1981; , and in rat experiments carried out in collaboration with Dr Hallmans' group at University of Umeå it could be shown that fat intake reduces enterolactone production in the gut . Recently it was found that a low compared to a high plasma enterolactone level is associated with considerably (about 60%) increased risk of breast cancer (Pietinen et al, 2001) . Antibiotics destroy the intestinal microflora and reduce the level of enterolactone in the body (Adlercreutz et al, 1986) , and young women who have been treated repeatedly with antibiotics for urogenital tract infections have increased breast cancer risk (Knekt et al, 2000) . However, the recent development of a simple, rapid and very sensitive method for plasma, urine and tissue enterolactone based on time-resolved fluorescence immunoassay (Adlercreutz et al, 1998; Stumpf et al, 2000) used in the present investigation has made it possible to study large materials. Furthermore it has been detected a number of new lignans in rye bran which can be converted to enterolactone by the intestinal microflora (Heinonen et al, 2001) . With the diet used in the present study the mean levels of plasma enterolactone were in the range giving the maximal effect on risk of the Western diseases. As long as we do not know whether enterolactone is the protective compound any further conclusions are not warranted.
Serum fatty acids
The amount of a-linolenic acid in flaxseed oil exceeds several-fold that of other vegetable oils. Alpha-linolenic acid is showing surprisingly similar targets of action as enterolactone. Processed meat and convenience foods are usually low in PUFAs. Flaxseed oil contains 66% of a-linolenic acid, 14% of linoleic acid and 10% of oleic acid. The ideal ratio of linoleic acid and a-linolenic acid in diet is not known but a ratio of 1:1 -2 has been considered beneficial to health with effects on cell membrane fluidity and membrane function (Simopoulos et al, 1999) . In Scandinavian diets this ratio is 1:4 -5, in Mediterranean countries 1:15 and in USA 1:10 -15. Flaxseed supplemented test food increased the ratio of these fatty acids to 1:1.6 and caused a significant rise of serum alinolenic acid. In single test foods a ratio of 1:1 was measured in sausages and meat balls. According to available literature levels like these are associated with reduced risk of cancer and coronary heart disease (De Lorgeril et al, 1994; Hartman, 1995; Hu et al, 1999; Rose, 1993) . Also serum values of eicosapentaenoic acid and docosapentaenoic acid were increased but not those of docosahexaenoic acid. This finding, reflecting elongation and desaturation of a-linolenic acid, is in agreement with previous studies on the effects of canola rapeseed oil, another dietary source of a-linolenic acid (Valsta et al, 1996) . Serum linoleic acid tended to increase but it was not significant.
Serum lipids
There were no changes in plasma lipid values during the diets. Most of the flaxseed-based supplementations in the test diet originated from the flaxseed oil and the smaller part came from ground flaxseed. Flaxseed oil has not shown any hypolipidemic effect (Nelson & Chamberlain, 1995) . Instead, ground flaxseed can lower both total and LDL-cholesterol and triglycerides. In our study we noticed slight but not significant reduction in total and LDL-cholesterol and in Effect of flaxseed supplementation S Tarpila et al triglycerides, particularly during the 4 months open phase. Also a slight but non-significant increase of HDL-cholesterol was shown in the open phase of the study. Our study shows that possible health-promoting effects due to increased levels of enterolactone and n-3 fatty acids in the serum can be achieved by including flaxseed fiber and oil as processed foods into the daily diet to cover 20% of daily energy intake. The use of processed meats and convenience foods is increasing with today's Western lifestyle. The consumption of meat can be reduced and its fat composition can be improved by substituting part of the meat with flaxseed preparations which may be beneficial factors in public health.
